Amar Arunachalam
Endocrinology, Diabetes & Metabolism · Palm Springs, FLNPI 1750842118
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,977, 9.8 times the $201 reported in 2023. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in FL, where the typical reported total is $3,445.
Across 103 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$309
- Medtronic$278
- Corcept Therapeutics$262
- Lilly USA, LLC$236
- Boehringer Ingelheim$175
- Insulet Corporation$151
- plus $921 from 17 others
What the payments were for
- Food & beverage$2,28798%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $309 |
| Medtronic | 4 | $278 |
| Corcept Therapeutics | 15 | $262 |
| Lilly USA, LLC | 8 | $236 |
| Boehringer Ingelheim | 7 | $175 |
| Insulet Corporation | 9 | $151 |
| Bayer | 5 | $133 |
| Xeris Pharmaceuticals, Inc. | 6 | $119 |
| Sanofi-aventis U.S. LLC | 3 | $113 |
| Mannkind Corporation | 4 | $87 |
| Recordati_rare_diseases_inc. | 3 | $69 |
| Ascendis Pharma Endocrinology Inc | 3 | $64 |
| Amgen | 3 | $59 |
| AbbVie | 3 | $59 |
| Novartis | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| AstraZeneca | 1 | $31 |
| GSK | 1 | $23 |
| Soleno Therapeutics, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$238
How this compares
$2,332 in reported general payments places this provider in the 40th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Other endocrinology, diabetes & metabolism in Palm Springs
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
- Misha DenhamCoral Gables$673K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.